High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 48, Issue 1, 2003, Pages 166-173

  Petri, Michelle ^a   Jones, Richard J ^a   Brodsky, Robert A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYCHLOROQUINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; TRIAMCINOLONE;

ADULT; ARTICLE; AUTOGRAFT; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; EFFECTOR CELL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; THROMBOCYTE TRANSFUSION;

EID: 0037235945     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10752     Document Type: Article

References (29)

1. Davis JC, Tassiulas IO, Boumpas DT. Lupus nephritis. Curr Opin Rheumatol 1996;8:415-23.
2. Gourley MF, Austin HA III, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med 1996;125:549-57.
3. McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988;318:1423-31.
4. Boumpas DT, Austin HA III, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993;119:366-9.
5. Bateman H, Yazici Y, Leff L, Peterson M, Paget SA. Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study. Lupus 2000;9:542-4.
6. Burt RK, Traynor AE, Pope R, Schroeder J, Cohen B, Karlin KH, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998;92:3505-14.
7. Brodsky RA, Smith AD. Bone marrow transplantation for autoimmune diseases. Curr Opin Oncol 1999;11:83-6.
8. Snowden JA, Brooks PM, Biggs JC. Haemopoietic stem cell transplantation for autoimmune diseases. Br J Haematol 1997;99:9-22.
9. Traynor AE, Schroeder J, Rosa RM, Cheng D, Stefka J, Mujais S, et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study, Lancet 2000;356:701-7.
10. Karussis DM, Slavin S, Ben-Nun A, Ovadia H, Vourka-Karussis U, Lehmann D, et al. Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation. J Neuroimmunol 1992;29:201-10.
11. Pestronk A, Drachman DB, Adams RN. Treatment of ongoing experimental myasthenia gravis with short term high dose cyclophosphamide. Muscle Nerve 1982;5:79-84.
12. Jacobs P, Vincent MD, Mantel RW. Prolonged remission of severe refractory rheumatoid arthritis following allogeneic bone marrow transplantation for drug-induced aplastic anemia. Bone Marrow Transplant 1986;1:237-40.
13. Lowenthal RM, Cohen ML, Atkinson K, Biggs JC. Apparent cure of rheumatoid arthritis by bone marrow transplantation. J Rheumatol 1993;20:137-40.
14. Euler HH, Marmont AM, Bacigalupo A, Fastenrath S, Dreger P, Hoffknecht M, et al. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood 1996;88:3621-5.
15. Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood 1996;87:491-4.
16. Brodsky RA, Sensenbrenner LL, Smith BD, Dorr D, Seaman PJ, Lee SM, et al. Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med 2001;135:477-83.
17. Brodsky RA, Petri M, Smith BD, Seifter EJ, Spivak JL, Styler M, et al. Immunoablative high-dose cyclophosphamide without stem cell rescue for refractory, severe autoimmune disease. Ann Intern Med 1998;129:1031-5.
18. Jones RJ, Barber JP, Vala MS, Collector MI, Kaufmann SH, Ludeman SM, et al. Assessment of aldehyde dehydrogenase in viable cells. Blood 1995;85:2742-6.
19. Sahovic EA, Colvin M, Hilton J, Ogawa M. Role for aldehyde dehydrogenase in survival of progenitors for murine blast cell colonies after treatment with 4-hydroperoxycyclophosphamide in vitro. Cancer Res 1988;48:1223-6.
20. Gordon MY, Goldman JM, Gordon-Smith EC. 4-hydroperoxycyclophosphamide inhibits proliferation by human granulocyte-macrophage colony-forming cells (GM-CFC) but spares more primitive progenitor cells. Leuk Res 1985;9:1017-21.
21. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
22. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
23. Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 1992;19:53-9.
24. Barr SG, Zonana-Nacach A, Magder LS, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 1999;42:2682-8.
25. Metropolitan Life Insurance Company. Ideal weights for women. Stat Bull 1942;23:6-8.
26. Metropolitan Life Insurance Company. Ideal weights for men. Stat Bull 1943;24:6-8.
27. Burt RK, Burns W, Hess A. Bone marrow transplantation for multiple sclerosis. Bone Marrow Transplant 1995;16:1-6.
28. Rosen O, Thiel A, Massenkeil G, Hiepe F, Haupl T, Radtke H, et al. Autologous stem-cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cells. Arthritis Res 2000;2:327-36.
29. Tyndall A, Gratwohl A. Immune ablation and stem-cell therapy in autoimmune disease: clinical experience. Arthritis Res 2000;2: 276-80.